9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays

Condition Peritoneal Mesothelioma Estimated Enrollment: 33 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Retrospective Study ID Numbers: D50828 Study First Received: April 27, 2016 Last Updated: July 25, 2016 Estimated Primary Completion Date: January 2016 Primary Outcome Measures: BAP1 mutations Sponsors and Collaborators: Hospices Civils de Lyon Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02834234...

Continue reading

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

Condition Malignant Pleural Mesotheliomas Estimated Enrollment: 50 Age Group: 39 Years to 84 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort|Time Perspective: Retrospective Study ID Numbers: DR-81 Study First Received: October 28, 2015 Last Updated: May 29, 2016 Estimated Primary Completion Date: May 2016 Primary Outcome Measures: to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival|assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result...

Continue reading

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 11 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 09-142 Study First Received: December 2, 2009 Last Updated: April 21, 2015 Estimated Primary Completion Date: July 2012 Primary Outcome Measures: To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated With Everolimus as Second or Third Line Therapy. Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute|University of Pennsylvania Result Received: April 7, 2015 Website Link: https://ClinicalTrials.gov/show/NCT01024946...

Continue reading

Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 20 Age Group: 20 Years to 75 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 10512|H3E-JE-ME02 Study First Received: October 10, 2006 Last Updated: April 10, 2007 Estimated Primary Completion Date: null Primary Outcome Measures: To investigate safety profile when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients|To investigate efficacy when administered pemetrexed combined with cisplatin in malignant pleural mesothelioma patients Sponsors and Collaborators: Eli Lilly and Company Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00386815...

Continue reading

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

Condition Mesothelioma Estimated Enrollment: 19 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2005-0288|NCI-2012-01381 Study First Received: November 20, 2006 Last Updated: November 16, 2015 Estimated Primary Completion Date: February 2014 Primary Outcome Measures: Maximum Tolerated Dose (MTD) of Cisplatin, Pemetrexed, and Imatinib Mesylate Given to Participants with Unresectable or Metastatic Malignant Mesothelioma Sponsors and Collaborators: M.D. Anderson Cancer Center|Novartis Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00402766...

Continue reading

Tomotherapy Treatment for Mesothelioma

Condition Mesothelioma Estimated Enrollment: 18 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: LU-11-0077 / 22933 Study First Received: May 2, 2007 Last Updated: April 5, 2016 Estimated Primary Completion Date: May 2015 Primary Outcome Measures: Quality of Life|Breathing Function|Survival/Response Rate Sponsors and Collaborators: AHS Cancer Control Alberta Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00469196...

Continue reading

Serum Biomarkers in Diagnosis of Mesothelioma

Condition Mesothelioma Estimated Enrollment: 230 Age Group: 18 Years to 85 Years   (Adult, Senior) Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Retrospective Study ID Numbers: 2010-280-1 Study First Received: January 6, 2014 Last Updated: January 6, 2014 Estimated Primary Completion Date: December 2010 Primary Outcome Measures: Serum N-ERC/mesothelin, C-ERC/mesothelin, hyaluronan, osteopontin and syndecan -1 level in the patients with mesothelioma, metastatic malignant pleural diseases, benign pleural diseases, and benign asbestos pleurisy. Sponsors and Collaborators: Eskisehir Osmangazi University Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02029105...

Continue reading

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Condition Mesothelioma Estimated Enrollment: 37 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 03-369 Study First Received: August 29, 2005 Last Updated: December 23, 2011 Estimated Primary Completion Date: March 2007 Primary Outcome Measures: To determine the response to the combination of bevacizumab and erlotinib in previously treated malignant mesothelioma|To determine the time to tumor progression|to determine the duration of response|to determine the median and overall survival of patients|to determine the safety of the drugs administered Sponsors and Collaborators: Dana-Farber Cancer Institute|Massachusetts General Hospital|University of Chicago Result Received: No Study Results Posted Website Link:...

Continue reading